GLRX and metabolic dysfunction-associated steatohepatitis: Pre-clinical studies using an adeno-associated viral vector demonstrated that administration of Glrx specifically targeting hepatocytes attenuates fibrosis and inflammation in the liver of diet-induced MASH mice (153).